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Sllmmary 
A population of cells that express mast cell markers, including the membrane protein p161, but 
that lack expression of the high affinity IgE receptor, FceRI, can be routinely grown from bone 
marrow. Ionomycin, but not IgE immune complexes, causes these cells to release serotonin and 
to express IL-3 and IL-13 mRNA, consistent with their being FCeRI-deficient mast cells. These 
p161 +/FceRI-  mast cells expressed normal amounts of FceRI c~ and B chain mRNA, but 
extremely low levels of FceRI3, chain mRNA. In addition, this novel mast cell population expressed 
CD3~" chain mRNA, which p161 +/FceRI + mast cells did not. CD3~" stable transfectants of 
Abelson-murine leukemia  virus-transformed p161  +/FceRI + mast  cells continued to express 
FceRI.  This  strongly suggests  that  the failure of p161+/FceRI -  mast cells to  express IgE 
receptors was not caused by the presence of CD3~"  chain. Transfection of human FcelLI3~  cDNA 
into p161 +/FceRI- mast cells rescued IgE binding.  These stable transfectants released serotonin 
in response to cross-linkage of Fc~RI, demonstrating that the molecular defect of p161 +/FceRI- 
mast cells is indeed the loss of Fc~RI'y expression. 
M 
ast cells mediate allergic  inflammatory responses through 
the release  of vasoactive  mediators, chemotactic factors, 
arachidonic acid metabolites, and cytokines. Release of con- 
tents of exocytic granules is induced by a variety of stimulants 
including calcium ionophores,  the anaphylotoxins C5a and 
C3a, mellitin, substance P, and formyl-methiolated  peptides 
(1). In particular, antigen-mediated  cross-linkage of the high 
af~nity receptor for the Fc portion of IgE (FceR.I) and of 
a receptor for the Fc portion of IgG (Fc'yR.II/III) are potent 
physiologic stimuli for the release of the preformed medi- 
ators and for the synthesis and secretion of cytokines (for re- 
view see reference 2). 
FceRI is expressed on mast cells and basophils (for review 
see reference 3), Langerhans cells (4-6), eosinophils (7), and 
some monocytes (8). The receptor is a tetramer consisting 
of an o~ chain, a B chain, and a dimer of two 3( chains. Dis- 
ruption of the Fcel~Io~ chain gene results in the failure of 
knockout mice to express FceR.I and to develop systemic or 
local anaphylaxis in response to challenge with IgE  anti- 
dinitrophenyl (DNP)  1 and DNP-human serum albumin (9). 
This result demonstrates the dependence of IgE-mediated ana- 
phylactic responses on FcelLI. 
The FceRI3' chain is also a component of Fc'yR.III and 
1 Abbreviations used in this paper: cR.PMI/WEHI-3CM, complete RPMI 
supplemented  with  10%  WEHI-3-conditioned  medium;  DNP, 
dinitrophenyl; RT-PCR, reverse  transcriptase-PCR; SCF, stem cell factor; 
Tin50, melting temperature of PCR primers. 
can function with the T cell antigen receptor as part of the 
CD3 complex.  Importantly, the FceRI3, chain is required 
for signal transduction and proper assembly and expression 
of both FceRI and Fc~RIII (10, 11). Ablation of this gene 
results in loss of  expression of  both receptors, with concomi- 
tant mast cell and macrophage defects (12). 
Mast cell ontogeny has yet to be fully elucidated; a major 
limitation has been the lack of mast cell-specific antibodies. 
In the course of characterizing a newly derived mAb, K-l, 
which recognizes an antigen, p161, expressed on mast cells 
and on some populations  of macrophages, we encountered 
a population of mast cells in short-term bone marrow cul- 
tures that lacked surface FceRI (12a). These FceRI-deficient 
mast cells appear to constitute a physiologic cell population 
since they routinely occur in short term cultures of bone 
marrow cells in IL-3. They have been propagated in long- 
term culture. 
In this paper, we define the molecular basis for the failure 
of these cells to express FcdLI.  We show that they express 
normal levels of mRNA for FceRIrv and FceRI/~ chains and 
that they release serotonin in response to ionomycin, strongly 
indicating that  they are  mast  cells. However,  they have 
markedly diminished expression of FcelLI~/mRNA. Recon- 
stituting */chain through transfection restores both FceRJ 
expression and the capacity to release serotonin in response 
to IgE receptor cross-linkage, establishing that the failure of 
this mast cell population to express FceRI results from its 
defect in 3, chain expression. 
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Immunoglobulins/Reagents.  Purified 2.4G2 and FITC-labeled rat 
anti-mouse IgE were purchased from Southern Biotechnology As- 
sociates, Inc. (Birmingham, AL). IgE was purified as described (12a). 
I~I-labeled IgE was a kind gift from Dr. Henry Metzger (NIAID, 
NIH, Bethesda, MD). The mast cell-specific mAb K-1 has been 
previously described (12a).  Rabbit anti-mouse CD3g" polyclonal 
antisera was a generous gift from Dr. John O'Shea (National Cancer 
Institute,  Frederick,  MD). 
Cells.  The derivation  of the  FceRI + and  FceRI-  mast cell 
lines used in this work has been described previously (12a). Briefly, 
BALB/c mouse bone marrow cells were cultured in 10% WEHI-3 
supernatant for 7-10 d,  and cells were sorted on the basis of IgE 
binding and p161 expression.  Populations were maintained in RPMI 
1640 medium supplemented with 15% fetal bovine serum, 2 mM 
t-glutamine,  100 U/ml penicillin,  100/xg/ml streptomycin, and 
1 mM sodium pyruvate, all from Biofluids,  Inc. (Rockville, MD) 
(cRPMI), supplemented with 10% WEHI-3-conditioned medium 
(cRPMI/WEHI-3CM) and 20 ng/ml mouse stem cell factor (SCF), 
generously donated by Dr. Tom Huff (Virginia Commonwealth 
University, Richmond,  VA).  The mouse mast cell line CFTL-12 
has been described previously (13) and was maintained in cRPMI/ 
WEHI-3CM. The mouse T cell line B413 was kindly donated by 
Dr. Ronald Germain (NIH). The murine B cell lines A20.1  and 
013D5 have been described previously (14). Mouse splenocytes were 
prepared by the removal of BALB/c spleens,  followed by manual 
disruption. Bone marrow cells used as positive controls in FcR cross- 
linking studies were prepared by removing BALB/c mouse femur 
bone marrow cells, and growing these cells in cRPMI/WEHI-3CM 
for 6-8 d.  Bone marrow-derived macrophages were prepared by 
culturing BALB/c bone marrow cells in GM-CSF (40 ng/ml) or 
monocyte colony-stimulating factor (M-CSF) (40 ng/ml) for 10 d. 
Expression  Vectors.  The  mouse  full-length  CD3~" cDNA  in 
plasmid pFNEO  and  the  human  full-length  FceRIy cDNA in 
pBJNEO were the kind gift from Dr. Jean-Pierre Kinet (NIAID, 
NIH, Rockville, MD). 
Cell Transfections/Transformation.  Abelson transformation of IL- 
3-dependent  mast cells  derived from bone marrow cultures was 
carried out as described (15). For CD3~" or human FceRI3/trans- 
fection, 3  x  107 FceRI + or FceRI- mast cells, respectively,  were 
electroporated with 20/xg plasmid DNA at 1,500 V using an elec- 
troporator  (Isco,  Lincoln,  NE).  Cells  were grown  for 24  h  in 
cRPMI/WEHI-3  CM  and  20  ng/ml SCF,  then  plated  in  this 
medium with 2.5 mg/ml Geneticin (GIBCO BRL, Gaithersburg, 
MD). After 4 d, cells were replated in the same medium with 1.2 
mg/ml Geneticin.  After 10 d, Geneticin concentration was low- 
ered to 0.8  mg/ml. Cells were maintained in this medium for 2 
wk,  at which  time positive wells  were expanded. 
Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR).  RT- 
PCR was carried out using 500 ng total RNA,  specific primers 
(see below), lx  PCR buffer (Perkin Elmer Corp., Norwalk, CT), 
2  mM MgCI2 during  a  50-min  RT  step  at  37~  and  4  mM 
MgC12 during a 35-cycle  PCR step with an annealing tempera- 
ture  of 5~  below  the  melting  temperature  of PCR  primers 
(Tin50), as calculated  using the (G/C  x  4~  +  (A/T  x  2~ 
formula. Annealing was carried out for 15 s, followed by an exten- 
sion at 72~  for 30 s in a GeneAmp PCR System thermocycler 
(Perkin-Elmer Corp.,  Norwalk,  CT). 
PCR Primers and Sizes of Expected Products. 
Mouse FceRIa: sense, 5' ATGGTCACTGGAAGGTCTGCC; anti- 
sense,  5' GGTTGAGAGCAATAACCCCGT (675  bp). 
Mouse FceRI3: sense, 5' AGGAGCAGAGCAGATCTTGCT; anti- 
sense,  5' AAAGCAGCCGTCGTCTTCGGT (477  bp). 
Mouse FceRI'y: sense,5' ATGATCTCAGCCGTGATCTTG; anti- 
sense,  5' AGTCTCATATGTCTCCTGGCT (233  bp). 
Human FceRI3': sense, 5' ATGATTCCAGCAGTGGTCTTG; anti- 
sense,  5' AGCCAAAGAAGAATATGACCG (283 bp). 
CD3 ~': sense~ 5' AGCCCTGTACCTGAGAGCAA; antisense,  5' 
GGAACTGAAGAAGACAAATGT (506  bp). 
IL-3: sense,  5' ACTCCAAGCTTCAATCAG; antisense,  5' GAC- 
CATGTAGAATCTCAG  (337 bp). 
Ib4: sense, 5' GAATGTACCAGCAGCCATATC; antisense, 5' CTC- 
AGTACTACGAGTAATCCA (385 bp). 
Ib13: sense, 5' ACAGCTCCCTGGTTCTCTCA; antisense, 5' GCT- 
ACTTCGATTTTGGTATCGG (370 bp). 
Actin:  sense,  5'  GATGACGATATCGCTGCGCTG;  antisense, 
5' CCTGTATGCCTCTGGTCGTAC (440  pp). 
FACS  |  Analysis.  Cells were first stained with 10/~g/ml rat 
anti-mouse Fc3'RII/III (2.4G2) for 10 min at 4~  followed by 
10/~g/ml mouse IgE for 1 h at 4~  in staining buffer (PBS, 3%~ 
FCS, 0.1% sodium azide). Cells were then washed twice and stained 
with 10/zg/ml FITC-conjugated rat anti-mouse IgE, then washed 
twice and analyzed in  the presence of propidium iodide with a 
FACScan |  (Becton Dickinson & Co., Mountain View, CA). Con- 
trol  samples  were  stained  with  10  /zg/ml  2.4G2  and  FITC- 
conjugated rat  anti-mouse IgE. 
lesI-IgE-binding Assay.  Ceils were incubated at a concentration 
of 5  ￿  106/ml  in a volume of 0.5 ml with 200/~g/ml unlabeled 
IgE or medium for 30 min at 37~  followed by the addition of 
5/xg/ml '2sI-IgE for 30 min at 37~  Cells were then centrifuged 
through dibutyl phythalate oil in triplicate for 2 min at 15,000 rpm. 
Cell pellets were frozen on dry ice, and the bottoms of tubes con- 
taining pellets were cut  off and counted in a Beckman gamma 
counter. Molecules of IgE bound per cell were determined by stan- 
dard calculations. 
Northern Blotting.  Total RNA (20 #g) was electrophoresed on 
a i% formaldehyde agarose gel and transferred to supported nitrocel- 
lulose (Schleicher & Schuell, Inc., Keene, NH). Northern blots were 
probed  with  32p-labeled cDNAs  generated  by RT-PCR  as  de- 
scribed above. 
Western Blotting.  For detection of CD3~" protein in cell trans- 
fectants, 1  x  107 cells were washed with PBS/1  mM EDTA and 
resuspended in Triton X-100 lysis buffer (0.05 M Tris, 0.3 M NaC1, 
0.5% Triton X-100,  0.4 mM EDTA, 2.5 mM leupeptin, 2.5 mM 
aprotinin, and 10 mM PMSF (Sigma Chemical Co., St. Louis, MO) 
and incubated on ice for 10 min. Samples were centrifuged for 10 
min at  15,000  rpm in a microcentrifuge,  and supernatants were 
removed and mixed with 2x  sample reducing buffer (0.125 M Tris, 
20% glycerol, 10% 2-ME, 4.6% SDS, and 1% bromphenol blue 
(Sigma Chemical Co.). Samples were boiled 5 min before being 
subjected to SDS-PAGE  on  a  14%  gel and electroblotted to an 
Immobilon-P membrane (Millipore Corp., Bedford, MA).  Blots 
were probed with a rabbit polyclonal anti-mouse CD3~" antisera, 
and  developed  using  the  enhanced  chemiluminescence  (ECL) 
Western  blot  detection  system according to  the manufacturer's 
specifications  (Amersham Corp.,  Arlington Heights,  IL). 
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resuspended at 5  x  106/ml in cRPMI/WEHI-3CM, incubated 
for 1 h at 4~  with IgE or medium, washed twice, resuspended 
at 5  x  106/ml in cKPMI, and stimulated for 5 h at 37~  with 
nothing, ionomycin (1 #M), or rat anti-mouse IgE (10 #g/ml). 
Total RNA was harvested using the RNAzol procedure (Tel-Test, 
Friendswood, TX) according to the manufacturer's specifications. 
Serotonin Release Assay.  Cells  were resuspended at 106/ml in 
cRPMI/WEHI-3CM  containing  2  /~Ci/ml  5-hydroxy(G-3H)  - 
tryptamine creatinine sulfate (Amersham Corp.) for 1 h at 37~ 
washed twice, and incubated I h at 37~  in cR.PMI/WEHI-3CM 
with or without IgE (25 #g/ml). Cells were then placed  in 96-well 
flat-bottom plates (Costar Corp., Cambridge, MA) at a concentra- 
tion  of 10  s per  well  and  incubated  for  30  min  with  5  #M 
ionomycin or 30 ng/ml DNP coupled to BSA (DNP-BSA), gener- 
ously donated by Fred Finkleman (U.S. Health Service, Bethesda, 
MD). Reactions were stopped by the addition of 100/~1 cold RPMI 
followed by centrifugation.  Supernatants were harvested and ly- 
sates were made using 100/~1 lysis  buffer (50 mM Hepes, pH 7.5, 
0.5% NP-40, 1% SDS, 5 mM EDTA, 50 mM NaC1, 10 mM so- 
dium pyrophosphate, and 50 mM NaF). Supernatants and lysates 
were counted, and the percent radioactivity in supernatants was 
calculated. All samples were done in triplicate. 
Results 
Existence ~FceRI-d~cient Mast Cells.  We recently reported 
an mAb, K-l, which identifies a 161,000-D glycoprotein (p161) 
expressed on mouse mast cells and on some populations of 
macrophages (12a). During the course of characterizing the 
cells that express  p161, we observed that in bone marrow 
cell populations cultured in IL-3 for 7-10 d, ~10%  of the 
p161 + cells failed to bind IgE. The p161 +/FceR- cells were 
purified by cell sorting on day 7 and repurified on day 10 
of culture in IL-3. A FACS  |  analysis of staining of such cells 
with IgE and FITC-anti-IgE illustrates their failure to bind 
IgE (Fig.  1).  In addition to expression of p161, these cells 
had other characteristics that are of typical of mast cells. They 
exhibited mast cell morphology, including large metachro- 
matic granules upon staining with alcian blue or toluidine 
blue, they contained histamine, and they stained with both 
the anti-FcyRII/FcyRIII  antibody 2.4G2 and with antibodies 
specific for c-kit (12a). The cells used in this study had been 
maintained in culture with IL-3 for up to 2 yr, and they resem- 
bled phenotypically the cell population characterized in de- 
tail by Kinzer, C. A., et al. To confirm the lack of IgE binding 
found by FACS  |  analysis,  the ability of these cells to bind 
12SI-labeled IgE was measured. As shown in Table  1,  they 
failed to bind detectable amounts of IgE in this assay, under 
conditions in which 500 receptors  per cell could have been 
detected. By contrast, FceR § mast cells, prepared in parallel 
with the FceR- line, bound 22,800  molecules of IgE/cell, 
only somewhat less than the IL-3-dependent mast cell line 
CFTL-12 used here as a positive control. 
Activation of FceR-deficient Mast Cells.  To assess the acti- 
vation potential of the p161 +/Fceg- cell line, serotonin re- 
lease  by these cells  was  compared  to  release  by a  line of 
p161+/FceRI +  cells  that  had  been  prepared  in  parallel. 
A  Fc~R Positive  B  FcER  Negative  400,11 
Log Fluorescence 
Figure  1.  IgE receptor expression  by bone marrow-derived  mast cells. 
FACS  |  purified  p161  +/FceR  + (A) or p161 +/FceR- (B) mast cells grown 
in Ib3 for several months were stained with mouse IgE and FITC-rat 
anti-mouse  IgE (solid  lines) or FITC-rat anti-mouse  IgE alone (dotted  lines). 
Cross-linkage of IgE resulted in activation, in the form of 
serotonin release only from p161+/FceR + cells (Fig.  2 A). 
However, the calcium ionophore inonomycin induced sub- 
stantial serotonin release from both FceR  + and FceR- mast 
cells. 
Mast  cells  are  known  to  express  and  secrete  multiple 
cytokines after FceRI cross-linkage that is increased by the 
addition of IL-3 (16). We assessed the relative abilities of  FceR- 
deficient and FceR + mast cells to express  cytokine RNA 
after stimulation with IgE immune complexes.  As shown 
in Fig. 3, IgE immune complexes induced both IL-3 and IL- 
13 mRNA by p161 +/FceR + cells. However, no detectable 
mRNA for either IL-3 or IL-13 was detected in FccR-deficient 
cells in response to IgE cross-linkage. The calcium ionophore 
ionomycin stimulated expression of cytokine mRNA in these 
cells to the same extent as in FceR + cells. 
FceRI-deficient Mast  Cells  have Diminished  Expression of 
FceRI  7.  To assess the expression levels of FceRI or, B, and 
"y chains,  KNA extracted from FceR  +  or  FcER-deficient 
cells was used in Northern blotting experiments. Expression 
of mRNA for FceRI ol and ~ chains in Fcdk-deficient mast 
Table  1.  IgE Binding by p161-positive Cells 
12sI-IgE plus 
IgE Molecules 
Cell Type  Medium (cpm)  IgE (cpm)  bound per cell 
CFTL-12  2108  +  63  291  -+  23  3.49  x  104 
p161+/FceR+  1318  -+  24  197  +  14  2.28  x  104 
p161+/FceP-  282  -+  4  276  +-  11  <500 
Cells (2.5 x 106) were incubated  with 200/~g/ml IgE or medium  alone, 
followed by 5/~g/ml 12Sl-IgE. Cell pellet was collected after centrifu- 
gation through dibutyl  phthalate oil, and cpm were determined  and used 
to calculate the number of IgE molecules  bound per cell. 
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Figure  2.  Serotonin release by p161+/FceK +  or p161+/FcdL -  mast 
cells.  Cells  (1  x  106) were  pulsed  with  3H-5-hydroxytryptamine,  in- 
cubated with mouse IgE anti-DNP, washed,  and stimulated with DNP- 
BSA. Alternatively, cells were stimulated with 5 ~M ionomycin, IgE, or 
DNP-BSA alone. Data are means of triplicate samples, from one of three 
representative experiments. 
cells was similar to that of FceR + cells or of the mast cell 
line CFTL-12 (Figs.  4, A  and B). However, FceR-deficient 
mast cell expression of FceRI3~ was undetectable by Northern 
analysis in several experiments, although it could be detected 
by RT-PCR using optimized conditions (Fig. 4 C and data 
not shown). Similar results were obtained with three sepa- 
rate groups of cells. One of these lines was tested after cul- 
ture for no more than 2 mo. Furthermore, 3' message could 
not be  induced by a  variety of stimuli,  including PMA, 
ionomycin, PMA and ionomycin, and incubation with IgE 
immune complexes (data not shown). Since it is known that 
all three chains of FceRI are required for proper expression 
(17), this major decrease in FceRI  7  mRNA expression could 
explain the lack of IgE binding and of IgE-mediated sero- 
tonin release, as well as cytokine  production by FceR~/-defldent 
cells. 
pI61-positive Macrophages Fail to Express FceRIol.  Since the 
K-1 antibody also recognizes some macrophage populations, 
we  assessed  the  expression  of the  FceRIc~  chain  in  such 
p161 + macrophages.  Macrophages were derived from cul- 
tures of mouse bone marrow cells that had been grown in 
CSF-1 or GM-CSF, both of which express p161 (12a). These 
cells failed to express detectable mRNA for FcERI c~ chain, 
as detected by RT-PCR (Fig.  5). As expected, mast cell iso- 
lates,  including  the p161+/FceR-deficient  cells,  expressed 
easily detectable amounts of this message. These results,  cou- 
pled with antibody staining and morphological assessments, 
strongly support the conclusion that the p161 +/FceR-defi- 
cient cells are of mast cell lineage, not macrophage lineage. 
In view of this and of the finding that they are deficient in 
a chain involved in the expression of FcERI, we will denote 
this population  as "FceRI-ddicient mast cells." 
Expression  of CD3/" in  FceRI-deficient  Mast  Cells.  It  is 
known that the ~" chain of CD3 is homologous to FcERI'r 
Figure  3.  IgE-mediated induction of Ib3 and IL-13 message,  p161 + / 
FcER § or p161+/FceR -  mast cells (1  x  107) were incubated with mouse 
IgE (3 gg/ml), washed and stimulated with 10/~g/ml rat anti-mouse IgE 
for 5  h.  Alternatively,  cells were incubated in medium  alone and were 
left unstimulated or stimulated with  1 gM ionomydn.  Total RNA was 
harvested and Northern blots were probed with cDNAs specific for either 
Ib3  (A)  or IL-13  (B). 
(18), and that the 3' chain can appear in CD3 in place of or 
in combination with ~" (19-21).  Although human CD3~" can 
substitute for FceRI3, in assembly of FceRI (22) or Fc3,RIII 
(10),  mouse CD3~" is unable to yield functional expression 
of Fc~/glII in COS-7 cells (10). In an effort to assess expres- 
sion levels of FceRI3~-related proteins in the p161 +/FceRI- 
deficient mast cells, we carried out RT-PCR for CD3~" on 
total RNA derived from these cells and from p161 +/FcePd + 
cells.  As  anticipated  from  previous  reports  that  mouse 
mast cells do not express CD3~" chain (20),  p161 +/FceRI + 
mast cells were negative by RT-PCR for ~'. Surprisingly, CD3~" 
mRNA was clearly detectable in the FceRI-deficient mast 
cells by RT-PCR (Fig.  6).  Similar results were obtained in 
multiple experiments with separate cell isolates. Despite the 
fact that CD3~'mRNA was detectable by RT-PCK, we were 
unable to demonstrate it by Northern analysis, nor could we 
detect CD3~" protein by Western blotting techniques. This 
suggests  that  the level  of expression of CD3~" in  p161  +  / 
FcdLI-deficient ceils is quite low. 
CD3~"  Transfection Does  Not  Affect  FceRI  Expression  by 
FceRI + Mast Cells.  Although it  seemed more likely that 
a decrease in FceRI'y expression was responsible for the lack 
of FceRI expression, it also remained possible  that an ab- 
normal expression of CD3~" in p161+/FceRI-deficient cells 
might be responsible for this phenotype. To test this possi- 
bility, we created stable transfectants of FceRI + mouse mast 
570  FceRI-negative  Mast Cells Are Deficient  for 3/Chain Figure 4.  Expression  of  FceRI  ol,  B,  3`  chains  in  p161+/FceR +  and  p161+/FceR -  mast  cells.  Total  RNA  was  harvested  from  CFTL-12, 
p161+/FCeRI + or p161+/FceR -  mast cells or the murine B cell lines A20.1 and O13D5.  Northern blots were probed with cDNAs specific for FceRI ~x 
(A),  B  (B),  or  3' (C).  Locations  of expected bands are indicated. 
cells with mouse CD3~'. These cells had previously been trans- 
fected  with  the  Abelson  murine  leukemia  virus  DNA, 
resulting in the creation of an IL-3-independent mouse mast 
cell line. The high proliferative rate of this cell line made it 
an ideal choice for stable transfection. We obtained several 
clones that expressed CD3~', as determined by RT-PCR and 
Western blotting  (Fig.  7 A,  and data not shown). FACS  | 
analysis  of IgE binding  by these transfectants  showed no 
notable decrease in IgE binding from untransfected cells; in 
fact,  several  transfectants  showed a  slight  increase in  IgE 
staining (Fig.  7 B). Thus, it appears that aberrant expression 
of CD3~" is not responsible for the FceRI-deficient mast cell 
phenotype. 
Reconstitution of FceRIg, Restores IgE Binding and Respon- 
siveness in FcERI- Mast Cells.  To prove that  the FcEIkI- 
phenotype  of the  p161-positive/FceRI-deficient  cells  was 
caused by the observed lack of Fcelkly, we stably transfected 
the human FcetkI3,  gene coupled to a neomycin-resistance 
marker gene into an IL-3-dependent, FcERI-deficient mast 
cell isolate. A series of neomycin-resistant  isolates derived from 
this transfection were screened for the capacity to bind IgE 
(Fig. 8). These lines, although clearly capable of  binding IgE, 
appeared to express many fewer receptors than conventional 
p161 +/FceRI +  cells.  To  demonstrate  that  these  FceRI + 
transfectants actually expressed human FcelkI3,,  we carried 
out RT-PCR using primers that distinguished between mouse 
and human 3' chain mRNA. Three individual transfectants 
that  were capable of binding  IgE  were tested for human 
FceRI3, mRNA by RT-PCR, and all three proved to express 
this mRNA (Fig. 9 A). RT-PCR for mouse FcERI3, showed 
little or no mouse "), mRNA expressed by these cells. Indeed, 
human FcERI3' transfectants and cells transfected with a vector 
expressing only the neomycin-resistance gene actually appeared 
to  express  less  mouse  3'  mRNA  than  did  the  parental 
p161 +/FceRIq,-deficient cells  (data not  shown). 
To determine if expression of human FceRI3, also restored 
responsiveness to FceRI cross-linkage, we tested the human 
3' transfectants in the serotonin release assay system. Although 
these transfectants expressed much lower amounts of FceRI 
than did bone marrow-derived mast cells,  they responded 
quite well to FcERI cross-linkage, showing serotonin release 
levels that were commensurate with those seen using bone 
marrow-derived mast cells in previous experiments. Cells that 
expressed the antibiotic resistance gene alone did not release 
serotonin (Fig.  10). Similar results were obtained in several 
experiments using four separate clones expressing human 3/ 
chain and seven expressing only the neomycin resistance gene. 
The complete restoration of this IgE-mediated response in- 
dicates that FceRI  3, expression alone is able to correct the 
phenotype of FcERI-deficient mast cells, and that low levels 
of expression of FceRI are sufficient for substantial release 
of serotonin. 
Figure 5.  p161 +  macrophages  do  not  express 
FceRI~x.  Total  RNA  was  extracted  from  bone 
marrow-derived macrophages grown in CSF-1 or GM- 
CSF,  from  A20.1  B  cells,  or  from  p161+/FceR +, 
p161 +/FceR-,  or CFTIr  mast cells. RNA was sub- 
jected to ILT-PCR. using primers specific for FceRI (.,el), 
or  actin (B).  Sizes of expected  RT-PCR.  products  are 
indicated. 
571  Ryan  et  al. Figure 6.  FceRI-deficient mast cells express CD3~'.  Total RNA was 
extracted from  CFTL-12  mast  cells,  A20.3  B  cells,  p161+/FceR  +  or 
p161+/FceRI -  mast cells, and subjected to RT-PCR using primers specific 
for CD3~'. Blank sample contained all reactants  except R.NA. Sizes of ex- 
pected RT-PCR.  product is indicated. 
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Figure  8.  Transfection  of FceKI3, into FcelkI-deficient  mast cells re- 
stores  IgE binding.  FACS  |  analysis of p161+/FceRI + mast  cells (A), 
p161 +/FceRI-  mast cells (B),  or p161 +/FcelkI- mast cells transfected 
with human FceRI'y cDNA (C). Cells were stained with mouse IgE and 
FITC-rat anti-mouse IgE (solid  lines)  or FITC-rat anti-mouse IgE alone 
(dotted lines). Data is representative of eight individual FceKIy transfectants. 
Figure 7.  Transfection  of CD3~" into p161 +/Fc6RI §  mast cells does 
not inhibited FceRI expression.  IL-3-independent p161 +/FceKI + mast 
cells were transfected  with CD3~" as described.  (.4) Western blot analysis 
using polyclonal rabbit anti-mouse CD3~" antisera  was performed with 
total cell lysates  from  seven CD3~" transfectants,  the  parental p161+/ 
FceRI + mast cell line, or B413 murine T cells. Size of the expected pro- 
tein is indicated. All clones had previously been shown to express CD3g" 
by RT-PCK analysis  (data not  shown).  (B) FACS  |  analysis of CD3~'- 
expressing p161 +/FceRI + clones, p161 +/FceRl + mast cells, either trans- 
fected with CD3~" or untransfected (parental), or p161 +/FceRI-deficient 
mast cells were stained with mouse IgE and FITC-rat anti-mouse IgE 
(solid  lines)  or FITC-rat anti-mouse IgE alone (dashed lines).  FACS* profile 
of IgE/FITC-anti-lgE-stained  parental cells is shown relative to each clone 
for reference  (dotted  lines). 
Discussion 
Mast  cells are responsible for immediate  hypersensitivity 
reactions that can be mediated via cross-linking of IgE bound 
to surface FceKI by cognate antigen. The resulting degranu- 
lation and  synthesis of cytokines,  arachidonic acid metabo- 
lites,  and  other  active substances  have been  widely  studied 
(for review see reference 2). In this work, we have character- 
ized a novel population of murine mast cells that lack detect- 
able FceRI.  These  cells routinely appear in short  term  cul- 
tures of bone marrow cells in IL-3. They have been isolated 
on several occasions by cell sorting based on their expression 
of p161  and  lack  of binding  of IgE. 
572  FceRI-negative Mast Cells Are Deficient for 3' Chain Figure 9.  RT-PCR analysis for expression of human 
FceRI'y.  Total  RNA  extracted  from  p161  +/FceRI- 
mast cells transfected with human FceR.17, neomycin 
resistance  marker, or untransfected cells was subjected 
to RT-PCR analysis for human FceRl7 (A), or mouse 
actin (B). Plasmid DNA encoding human FcERI7 was 
used  as  a  positive control  in  (A).  Sizes  of expected 
RT-PCR products are indicated. 
Analysis of this population showed it to possess many mast 
cell characteristics, with the obvious exception of IgE binding. 
As described in more detail elsewhere (12a), FceRI-deficient 
mast cells  maintain their phenotype in IL-3 culture for at 
least 2 yr. Although we strongly suspect that these cells occur 
physiologically, based on their routine appearance in short 
term culture, they have not yet been identified in vivo or im- 
mediately ex vivo.  Since p161 is expressed on some macro- 
phage populations, particularly on thioglycolate-induced  peri- 
toneal macrophages, its expression on cells in vivo will not 
unambiguously identify them as mast cells. We have purified 
mast cells from peritoneal cavities of CBA/JCR mice by den- 
sity gradient centrifugation;  all  of the p161 +  cells  bound 
IgE, indicating that p161 +/Fc~RI-  mast cells were not a de- 
tectable component of this mast cell population.  We have 
not yet examined other mast cell populations in the detail 
required to  determine whether p161+/FceRI -  cells  are a 
major component. 
Long-term lines of FcelLI-deficient mast cells failed to re- 
spond to IgE cross-linkage in two assay systems. These cells 
could neither release serotonin nor produce cytokines, demon- 
strating a severe defect in both short- and long-term activa- 
tion responses. However, FcERI-deficient mast cells did re- 
spond to ionomycin, indicating intact signaling cascades and 
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Figure 10.  Transfection of F'ceRI  7  into FceRI-deficient mast cells re- 
stores  IgE  responsiveness,  p161+/FceRI -  mast  cells  transfected with 
human FceRl7 or neomycin resistance marker were assayed for serotonin 
release as described in Fig.  2. 
the  capacity  to  release  granule  contents  and  to  produce 
cytokines made by other mast cells. 
FceRI-deficient mast cdls are severely lacking in FcERI7 
expression,  mRNA  for  this  chain  was  undetectable  by 
Northern blot analysis, and it could not be induced by stim- 
ulation with immune complexes or phorbol esters, with and 
without calcium ionophores.  Also,  cells in long-term cul- 
ture with IL-3, with or without SCF, did not develop 3' ex- 
pression.  Studies involving the selective ablation of either 
FceRIo~ or FceRI7 (9, 23) have demonstrated normal mast 
cell development in the absence of FceRI expression. 
CD3~" and FceRI  7 are known to have been created via gene 
duplication; both are located on mouse chromosome 1, have 
similar intron/exon composition, and share 50% protein ho- 
mology. Both chains are expressed in some cell populations, 
induding T  cells and human NK cells (for review see refer- 
ences 24,  25).  The coincidental loss of Fc~RI7 in  FcERI- 
deficient mast cells, together with the unexpected expression 
of CD3~', suggests an altered regulation of these two genes 
in this population.  However, expression of CD3~" does not 
appear to be responsible for the loss of FceRI in our cell popu- 
lation since transfection of this chain into mast ceUs bearing 
Fc~RI had no notable effect on IgE binding. 
Rather, we show that the FceRI-deficient phenotype is in 
fact caused by the lack of FceRIT. Ahhough mouse FceRI7 
may have better complemented  the endogenous c~ and ~ chains, 
we chose human FceRI  7  for our transfection studies so that 
we could dearly demonstrate expression of transfected cDNA. 
The extremely low level of mouse FcERI7 mRNA detected 
by RT-PCR analysis of transfected cells indicates that we have 
not selected transfectants with upregulated endogenous mouse 
FceRI  7  or  a  minor population  of FceRI + contaminating 
cells.  Furthermore, only ceils  transfected with  the human 
FcERI7 cDNA showed expression of this chain by RT-PCR 
analysis. The increase in IgE binding by cells transfected with 
human FcdLI7 was modest but dear. More importantly, this 
degree of expression of FceKI appeared to convey full sig- 
naling potential to these cells, as judged by the serotonin re- 
lease assay, indicating that FceRI7 alone is sufficient to re- 
turn an IgE-responsive phenotype to  these cells. 
This population of FceRIT-deficient cells could be a useful 
model system for the study of both IgE and IgG receptors 
and the role they play in mast cell activation and signalling. 
Studies involving targeted disruptions of the FceRIo~ and 7 
genes have fully demonstrated the essential roles played by 
FceRI in anaphylaxis (9, 23). More importantly, the charac- 
terization of this novel mast cell population may provide critical 
insight into the understanding of mast cell ontogeny, which 
is  still  enigmatic. 
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